Research Article

ACUTE TOXICITY PROFILE OF CERVICAL AND UTERINE CANCER PATIENTS TREATED WITH CHEMORADIATION: A 10-YEAR REVIEW

Yusuf Tukur1*, Usman M. Aliyu2, Abubakar M. Bello3, Sunday A. Adewuyi4, Oladapo B. Campbell5, Aisha Mustapha6, Yusuf Dantani7, Ibrahim A. Umar8, Shehu Salihu Umar9
1 Department of Radiation and Clinical Oncology, Usmanu Danfodiyo University Teaching Hospital (UDUTH), Sokoto, Nigeria
2 National Institute for Cancer Research and Treatment (NICRAT), 43 Agadez Crescent, Wuse II, 900288, FCT-Abuja, Nigeria.
3 Department of Radiation and Clinical Oncology, National Hospital, Abuja
4 Department of Radiation and Clinical Oncology, Ahmadu Bello University Teaching Hospital Zaria, Nigeria.
5 Department of Radiation and Clinical Oncology, University College Hospital, Ibadan
6 Department of Obstetrics and Gynecology, Ahmadu Bello University, Zaria, Kaduna State, Nigeria
7 Department of Histo-Pathology, Usmanu Danfodiyo University Teaching Hospital (UDUTH), Sokoto, Nigeria
8 Department of Surgery, Usmanu Danfodiyo University Teaching Hospital (UDUTH), Sokoto, Nigeria.
9 Department of Radiology, Ahmadu Bello University Zaria, Kaduna State, Nigeria
* Corresponding author: ytukur06@gmail.com
Published: Feb, 2026
DOI: 10.67579/njo.2026.vpethnkx
Pages: 87-98
Views: 270
Downloads: 207

Abstract

Background: Radiation therapy is integral to treating many gynaecologic cancers.

Objective: We sought to determine the frequency and severity of acute toxicity in patients who had pelvic radiotherapy for cervical and uterine cancers.

Methods: A retrospective study of all women who had pelvic radiation for cervical and uterine cancers at Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria, from January 2010 to December 2019.


All cases of cervical and uterine cancers that met the inclusion criteria were studied. A structured pro forma was used to extract relevant data from patients’ case files and treatment cards. Information obtained included biodata, site and size of tumour, dose of radiation prescribed to the pelvis, date of completion of external beam radiotherapy (EBRT) as well as dose of radiation received from EBRT, cycles of chemotherapy, the cytotoxics used and dose, interval between both therapies, side effects during and after EBRT (follow-up), disease status on follow-up period. Toxicity profile was recorded based on Radiation Therapy Oncology Group (RTOG)/European Organisation for Research and Treatment of Cancer (EORTC) Late Radiation Morbidity Scoring Scheme.

Result: Most patients seen in the study were of the age group 41-50 years, with cervical cancer being by far the commoner of the two (2) gynaecological cancers treated with chemoradiation in this study. Majority of the cases were diagnosed at stage IIIA. The most prescribed radiation dose from EBRT was 50Gy in 25 fractions. The study showed that acute toxicity had a similar pattern as compared to studies conducted in other regions of the world. The acute toxicity profile of pelvic radiotherapy in women with cervical and endometrial cancer was found to be mainly mild to moderate. Gastrointestinal toxicity was the most frequently observed toxicity, followed by urinary and hematologic toxicity. In this study, most common acute reactions (64.9%) occurred in the gastrointestinal system, with 60.6% having grade 1 and 4.3% grade 2 toxicity for cervical cancer patients, while those with endometrial cancer recorded 50% grade 1 and 3% grade 2 toxicity.

Conclusion: The frequency and severity of acute toxicity of pelvic radiotherapy in women with gynaecologic cancers were found to be mild to moderate.


Keywords

Gynaecological malignancies Radiotherapy Chemotherapy Acute toxicity Cervical cancer Endometrial cancer Haematological toxicity Gastrointestinal toxicity Urinary toxicity

References

  1. Hafiz A, Abbasi AN, Ali N, Khan KA, Qureshi BM. Frequency and severity of acute toxicity of pelvic radiotherapy for gynecological cancer. J Coll Physicians Surg Pak. 2015;25(11):802.
  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
  3. Forbes LJ, Warburton F, Richards M, Ramirez A. Risk factors for delay in symptomatic presentation: a survey of cancer patients. Br J Cancer. 2014;111(3):581–8.
  4. Todo Y, Watari H. Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups. Chin J Cancer Res. 2016;28(2):221.
  5. Ost P, De Gersem W, De Potter B, Fonteyne V, De Neve W, De Meerleer G. Comparison of acute toxicity profile between two-dimensional and three-dimensional image-guided radiotherapy for postoperative prostate cancer. Clin Oncol (R Coll Radiol). 2011;23(5):344–9.
  6. Ugwu E, Iferikigwe S, Okeke T, Ugwu A, Okezie O, Agu P. Pattern of gynaecological cancers in University of Nigeria Teaching Hospital, Enugu, South Eastern Nigeria. Niger J Med. 2011;20(2):266–9.
  7. Mohammed A, Edino S, Ochicha O, Gwarzo A, Samaila A. Cancer in Nigeria: a 10-year analysis of the Kano cancer registry. Niger J Med. 2008;17(3):280–4.
  8. Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet. 2002;359(9312):1093–101.
  9. Adewuyi S, Shittu S, Rafindadi A. Sociodemographic and clinicopathologic characterization of cervical cancers in northern Nigeria. Eur J Gynaecol Oncol. 2008;29(1):61.
  10. Sowemimo OO, Ojo OO, Fasubaa OB. Cervical cancer screening and practice in low resource countries: Nigeria as a case study. Trop J Obstet Gynaecol. 2017;34(3):170–6.
  11. Ibrahim H, Ijaiya MA. Pattern of gynaecological malignancies at the University of Ilorin Teaching Hospital, Ilorin, Nigeria. J Obstet Gynaecol. 2013;33(2):194–6.
  12. Manzoor H, Naheed H, Ahmad K, Iftikhar S, Asif M, Shuja J, et al. Pattern of gynaecological malignancies in south western region of Pakistan: an overview of 12 years. Biomed Rep. 2017;7(5):487–91.
  13. Nnadi DC, Singh S, Ahmed Y, Siddique S, Bilal S. Histopathological features of genital tract malignancies in a tertiary health center in north western Nigeria: a 10-year review. Ann Med Health Sci Res. 2014;4(3):213–7.
  14. Anunobi C, Jagun O, Agboola A, Akintola P, Andu B. Clinico-pathological study of female genital malignancies in Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria. West Afr J Med. 2014;33(1):7–11.
  15. Banas T, Pitynski K, Okon K, Winiarska A. Non-endometrioid and high-grade endometrioid endometrial cancers show DNA fragmentation factor 40 (DFF40) and B-cell lymphoma 2 protein (BCL2) underexpression, which predicts disease-free and overall survival, but not DNA fragmentation factor 45 (DFF45) underexpression. BMC Cancer. 2018;18(1):1–11.
  16. Matsuo K, Mandelbaum RS, Machida H, Purushotham S, Grubbs BH, Roman LD, et al. Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix. J Gynecol Oncol. 2018;29(6):e91.
  17. Eze JN, Emeka-Irem EN, Edegbe FO. Six-year study of the clinical presentation of cervical cancer and management challenges at a state teaching hospital in southeast Nigeria. Clin Med Insights Oncol. 2013;7:CMO.S12017.
  18. Jereczek-Fossa BA, Badzio A, Jassem J. Factors determining acute normal tissue reactions during postoperative radiotherapy in endometrial cancer: analysis of 317 consecutive cases. Radiother Oncol. 2003;68(1):33–9.
  19. Peters WA III, Liu P, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Obstet Gynecol. 2000;55(8):491–2.
How to Cite

Tukur, Y., Aliyu, U. M., Bello, A. M., Adewuyi, S. A., Campbell, O. B., Mustapha, A., Dantani, Y., Umar, I. A., & Umar, S. S. (2026). ACUTE TOXICITY PROFILE OF CERVICAL AND UTERINE CANCER PATIENTS TREATED WITH CHEMORADIATION: A 10-YEAR REVIEW. Nigerian Journal of Oncology, 2(1), 87-98. https://doi.org/10.67579/njo.2026.vpethnkx

Y. Tukur, U. M. Aliyu, A. M. Bello, S. A. Adewuyi, O. B. Campbell, A. Mustapha, Y. Dantani, I. A. Umar, and S. S. Umar, "ACUTE TOXICITY PROFILE OF CERVICAL AND UTERINE CANCER PATIENTS TREATED WITH CHEMORADIATION: A 10-YEAR REVIEW," Nigerian Journal of Oncology, vol. 2, no. 1, pp. 87-98, February 2026. doi: 10.67579/njo.2026.vpethnkx

Share this article:
Facebook X / Twitter LinkedIn
Download PDF View Full Text (PDF) Back to Articles